Longeveron is a clinical-stage biotechnology company developing cellular therapies derived from the body's own cells to repair and regenerate tissues affected by chronic aging-related diseases, including Alzheimer’s and aging frailty. Their research focuses on enhancing healthspan by improving endogenous repair mechanisms, addressing the decline in health associated with aging and life-threatening conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic aging-related diseases and certain congenital conditions result from the body's diminished capacity to repair and regenerate damaged tissues. Current treatments often fail to address the underlying causes of tissue degeneration, leading to limited efficacy and a decline in overall healthspan.
Solution
Longeveron is a clinical-stage biotechnology company developing cell-based therapies, including its lead investigational product, Lomecel-B™ (laromestrocel), to address tissue repair and regeneration. Lomecel-B™ consists of medicinal signaling cells (MSCs) and is being evaluated for its potential to improve outcomes in aging-related conditions such as Alzheimer's disease and aging frailty, as well as life-threatening conditions like Hypoplastic Left Heart Syndrome (HLHS). The company's approach focuses on enhancing the body's endogenous repair mechanisms to improve healthspan, the period of life spent in good health. Clinical trials are underway to assess the safety and efficacy of Lomecel-B™ in these therapeutic areas, with the goal of developing regenerative medicines that can restore tissue function and improve the quality of life for patients.
Target Audience
The primary target audience includes individuals affected by aging-related diseases such as Alzheimer's disease and aging frailty, as well as infants with life-threatening congenital heart defects like Hypoplastic Left Heart Syndrome (HLHS).
Features
- Utilizes allogeneic medicinal signaling cells (MSCs) for potential regenerative effects
- Investigational product Lomecel-B™ (laromestrocel) is currently in Phase 1, 2, and 2b clinical trials
- Clinical programs targeting Alzheimer's disease, Aging Frailty, and Hypoplastic Left Heart Syndrome (HLHS)
- Proprietary manufacturing process for consistent and scalable cell therapy production
- Granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for Lomecel-B™ in mild Alzheimer's disease
- Granted Fast Track designation by the FDA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
- ELPIS II Phase 2b clinical trial for HLHS is designed as a pivotal trial with potential for BLA submission
- CLEAR MIND Phase 2a clinical trial in Alzheimer's disease demonstrated improvements in cognitive function and brain volume